In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to determine Harmless dosing regimen. More contributors will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be presented as "increase-on" therapy. In https://abbv-744-clinical-trial-p23578.bligblogging.com/32611971/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets